Breaking News Headlines Today | Ground News

Holiday Sale — Get 40% off Vantage for yourself or as a gift

HubSite 365 image

News from HubSite 365

HubSite 365’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

HubSite 365’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about HubSite 365

Where is HubSite 365 located?HubSite 365's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top HubSite 365 News

Horrifyingly Offensive AI Videos Using Disney’s IP Are Already Appearing on Sora Only a Few Days After Signing $1 Billion Deal

Horrifyingly Offensive AI Videos Using Disney’s IP Are Already Appearing on Sora Only a Few Days After Signing $1 Billion Deal

80% Center coverage: 5 sources

Just days after Disney announced its $1 billion investment with OpenAI, the company is already seeing the horrifying impact this could have on its intellectual property. Users have already started using Disney’s IP to create inappropriate, sexist, and racist videos using AI-generated clips on Sora. Credit: Canva Among the videos that people have created are Pixar-esque videos featuring Jeffrey Epstein as the main character, as well as a recreati…See the Story

Mazdutide versus Dulaglutide in Chinese Adults with Type 2 Diabetes

European Union · Canada

Mazdutide versus Dulaglutide in Chinese Adults with Type 2 Diabetes

Coverage: 5 sources

Mazdutide is a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D) 1. This study assessed the efficacy and safety of mazdutide versus dulaglutide in participants with T2D on background oral anti-diabetic drugs. In this randomised phase 3 study, 731 participants with T2D were randomised 1:1:1 to receive mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks. Both m…See the Story

Shared Genetic Risk in Psychiatric Disorders

Education · Xi'an

Shared Genetic Risk in Psychiatric Disorders

100% Center coverage: 1 sources

Scientists have characterized the broad genetic patterns that are shared across 14 psychiatric disorders. Could it reframe how mental-health conditions are diagnosed? Scientists have characterized the broad genetic patterns that are shared across 14 psychiatric disorders. Could it reframe how mental-health conditions are diagnosed?See the Story

Breaking News Topics Related to HubSite 365